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Two types of radioimmunoassay (RIA) methods for measuring endothelin (ET) in human plasma were developed. One 
was an extraction procedure using a Sep-Pak C18 cartridge, the other being a direct method. By the extraction method, 
plasma ET levels were lower than the detectable limit (7 pg/ml) in normal subjects and elevated in hemodialysis patients. 
The absolute values obtained via the direct method were 20-times higher than those from extraction. Gel-filtration experi- 
ments revealed that this discrepancy was mainly due to immunoreactive (IR-) endothelin-like substances ofhigh molecu- 
lar mass near 11.6 kDa (large IR-ET). Extraction of the peptide by the C18 cartridge could eliminate interference by 
large IR-ET and is important in the accurate measurement of ET concentrations i  plasma. 
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1. INTRODUCTION 
Endothelin (ET), a novel 21-residue vasocon- 
strictor peptide, was recently discovered by Yana- 
gisawa et al. [1]. ET is known to elevate the arterial 
blood pressure of rats and it has been suggested 
that disturbances in the control of ET production 
contribute to the pathogenesis of hypertension 
[1,2]. However, it remains unknown as to whether 
ET exists in human plasma. Here, we have 
developed highly sensitive and specific radio- 
immunoassay (RIA) systems for ET and surveyed 
immunoreactive (IR-) ET in human plasma. Two 
types of RIA were employed: one for extraction us- 
ing a Sep-Pak C18 cartridge and the other for a 
direct procedure necessary for future studies using 
small animals. 
2. MATERIALS AND METHODS 
normal subjects (6 men, 4 women; 34.7 _+ 15.5 years, 
mean + SD) and 32 patients with chronic renal failure (16 men, 
16 women; 58.1 ± 13.0 years) undergoing hemodialysis (HD) 
2-3 times per week for 3-5 h per session. Blood samples were 
collected from peripheral veins in the morning before breakfast 
after 30 min of recumbency in normal subjects. In HD patients 
blood samples were collected from the forearm subcutaneous A- 
V fistula before dialysis. The blood was transferred toa chilled 
tube containing EDTA and Trasylol, and centrifuged at 3000 
rpm for 10 min at 4°C. The plasma was stored at - 20°C until 
assayed. 
2.2. Extraction procedure 
Extraction of ET was as follows: 3 ml of each plasma sample 
was acidified with 6 ml of 4°70 acetic acid and applied to a Sep- 
Pak C~8 cartridge (Waters, Milford, MA). The adsorbed peptide 
was eluted with 2 ml of 60070 acetonitrile in 0.5070 ammonium 
acetate, dried down under compressed air, reconstituted in 0.5 
ml assay buffer, and subjected to RIA. The assay buffer used 
for RIA was 0.1 M phosphate buffer (pH 7.7), containing 0.1070 
human serum albumin, 0.2070 Triton X-100 and 0.1 °70 NAN3. ET 
was also extracted from 1 1 of diaiysate from a HD patient via 
the same procedure. 
2.1. Blood samples 
The studied population consisted of 42 subjects, including 10 
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2.3. Radioimmunoassay method 
Synthetic human ET and ET antisera were purchased from 
the Peptide Institute (Osaka). ET was radioiodinated using a~ 
modified chioramine-T method [3], labeled ET being purified 
on a Sephadex G-50 superfine column (1 × 25 cm) as described 
[4]. 
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First, 0.2 ml of sample (standard solution or reconstituted ex- 
tract) was incubated with 0.1 ml diluted antibody (final dilution 
1/10000) at 4°C for 48 h. For direct assays, 0.1 ml of sample 
plasma or charcoal-treated plasma, 0.1 ml assay buffer or stan- 
dard solution and 0.1 ml antibody at the same dilution as used 
in the extraction were incubated. 0.1 ml 125I-ET (approx. 3000 
cpm) was then added, followed by a further incubation for 24 h 
at 4°C. Free and bound ligands were separated by a secondary 
antibody immunoprecipitation techniques as in [4]. 
2.4. Gel filtration and high-performance liquid 
chromatography 
3 ml plasma from HD patients was run on a Sephadex G-50 
superfine column (1.8 x 44 cm) at 0.3 ml/min. The eluent was 
1 M acetic acid and fractions of  2 ml were collected, dried down 
and assayed as described. Reverse-phase high-performance 
liquid chromatography (HPLC) of the extracts from 60 ml 
pooled plasma of HD patients and from 1 I of dialysate was per- 
formed on a column of M-Bondapak C18 (3.9 x 300 mm, 
Waters). A linear gradient elution system was employed from 30 
to 60% acetronitrile in 0.1% trifiuoroacetic acid over 30 min. 
The flow rate was 1.0 ml/min,  and fractions of 2 ml were col- 
lected, dried down, reconstituted and assayed as described. 
Results are expressed as means + SD. 
3. RESULTS 
3.1. Characteristics of the radioimmunoassay 
Fig. 1 shows a standard curve for the extraction 
method, derived from 10 consecutive assays, and 
serial 2-fold dilution curves of a plasma extract and 
plasma of 3 HD patients. The standard curve for 
the direct method was the same as that from extrac- 
tion (not shown). The minimum detectable imit of 
ET was 5.0 pg per tube (P<0.001, n = 10, t-test). 
Intra- and inter-assay coefficients of variation were 
7.6% (n = 8) and 8.1°70 (n = 8), respectively. 
Recoveries ranged from 48 to 7507o (58 _+ 807o, 
n = 8). Cross-reactivities were 0.00207o with rat 
ET, and zero with other peptides tested, including 
human or-atrium natriuretic peptide, porcine brain 
natriuretic peptide and ~2-microglobulin. 
The dilution curve of the plasma extract parallel- 
ed the standard curve, however those for plasma of 
3 HD patients did not. 
3.2. Gel filtration and HPLC 
Fig.2 illustrates that results, obtained by gel 
filtration, a single major immunoreactive peak, 
peak 1, being observed. Peak 1 eluted at a position 
of little before that of ~2-microglobulin. Serially 
diluted fractions from peak 1 (nos 31-40) inhibited 
radioligand binding in parallel with standard solu- 
tions of synthetic endothelin (fig. 1). 
Fig.3A and B illustrates the HPLC results for a 
plasma extract from hemodialysis patients and a 
dialysate extract, respectively. Two major im- 
munoreactive peaks were observed and the later 
peak co-migrated with synthetic ET. 
3.3. Studies in normal subjects and hemodialysis 
patients 
Using the extraction method, plasma IR-ET was 
undetectable in normal subjects (fig.4A). In con- 
trast, plasma IR-ET was detectable in 24 of 32 HD 
patients (10.9 _+ 3.4 pg/ml, n = 24). 
Employing the direct method, IR-ET was de- 
tectable in 1 of 10 normal subjects and in 31 of 32 
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Fig. 1. Standard curve for the extraction method (e) and serial 
2-fold dilution curves of a plasma extract (©), fractions 31-40 
from gel filtration (El) and plasma of 3 hemodialysis patients 
(A,v,o). 
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Fig.2. Gel-filtration profile of  immunoreactive endothelin (IR- 
ET) in plasma of a hemodialysis patient. Arrows indicate the 
elution positions of ~2-microglobulin (/]2MG) and synthetic ET 
(ET), respectively. 
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Fig.3. Analysis of immunoreactive (IR-) endothelin (ET) in a plasma extract (A) and a dialysate xtract (B) by reverse-phase HPLC. Ar- 
rows indicate the elution position of synthetic ET. 
HD patients (217 + 104 pg/ml, n = 31) as shown 
in fig.4B. 
4. DISCUSSION 
Here, we have found that at least two types of 
IR-ET exist in plasma of HD patients. One type is 
detectable with the extraction procedure. It seems 
likely that this substance is identical to ET on the 
basic of the finding that it eluted at the same posi- 
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Fig.4. Immunoreactive endothelin (IR-ET) levels in plasma of 
normal subjects and hemodialysis patients (HD) measured by 
the extraction (A) and direct (B) method. Values below the limit 
of sensitivity are plotted within the stippled areas. 
tion as synthetic ET in HPLC (fig.3). The other 
substance gave a single major peak in gel filtration 
(peak 1) with a molecular mass greater than 11.6 
kDa of/5'2-microglobulin (fig.2). The IR-ET-like 
substance, tentatively designated large IR-ET, was 
also detectable via the direct method and had 
plasma levels 20-fold those of ET (fig.4). The fact 
that the dilution curve of large IR-ET paralleled the 
standard curve suggests that large IR-ET is a 
precursor of ET. Large IR-ET is probably on in- 
termediate produced from preproendothelin [2] 
through unknown processing. 
The findings that the dilution curves of plasma 
from HD patients were not parallel with the stan- 
dard curve may indicate the existence of unknown 
substances in plasma of HD patients which ac- 
celerate radioligand binding in the RIA system. 
From these results, we tentatively conclude that the 
extraction of endothelin with the Sep-Pak Cls car- 
tridge is particularly important for accurate 
measurement of ET concentrations in plasma. 
Our extraction method with a detection limit of 
5 pg/tube was as highly sensitive as an RIA system, 
but not enough to detect ET in plasma of normal 
subjects. ET levels of normal subjects were 
estimated to be lower than 7 pg/ml. In contrast, 
plasma ET levels were elevated in HD patients 
(fig.4), but the physiological meaning of this eleva- 
tion remains obscure in the present study. The 
elevated level of ET in HD patients might suggest 
impaired metabolism and excretion of ET, in keep- 
ing with the cases of many other peptide hormones 
and neuropeptides, by the decreased renal func- 
tions [5]. 
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